Anti-ErbB3 antibodies

US9228021B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Sylvie Vincent · Somerville, US
• William M. Winston, Jr. · Marlborough, US
• Fang Wang · Fujian, CN
• Solly Weiler · Newton, US
• Kristan Meetze · Lexington, US
• Lyne Breault · Brookline, US
• Steve Bottega · Cambridge, US
• Ting Chen · Austin, US
• Michael DePrima · Somerville, US
• Christina Fleet · Melrose, US
• Steven Tyler · Boston, US
• Jin-Kyeung Woo · Newton, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Jun 17, 2013
• Grant date: Jan 5, 2016
• Expiry date: Jul 1, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.